Minus und Minus iss immer BLUS
| eröffnet am: | 01.07.15 06:23 von: | buran |
| neuester Beitrag: | 25.04.21 01:26 von: | Annettbwnua |
| Anzahl Beiträge: | 26 | |
| Leser gesamt: | 8524 | |
| davon Heute: | 4 | |
bewertet mit 0 Sternen |
||
|
|
||
0 Postings ausgeblendet.
07.07.15 20:49
#6
buran
drüben knapp 17 Tausend anne Tafel RT
Buch
http://www.ariva.de/bellus_health-aktie/times_and_sales?boerse_id=83 GrB
http://www.ariva.de/bellus_health-aktie/times_and_sales?boerse_id=83 GrB
16.08.15 15:18
#10
buran
Shareholder Information
http://www.bellushealth.com/English/investors/...rmation/default.aspx GrB
16.08.15 15:22
#13
buran
August 12, 2015
BELLUS Health narrows timelines for the Phase III study for KIACTA™ and reports financial and operating results for the second quarter ended June 30, 2015 - See more at: http://www.bellushealth.com/English/investors/...sthash.MstvgETk.dpuf http://www.bellushealth.com/English/investors/...verview/default.aspx
16.08.15 15:24
#16
buran
Corporate Profile
BELLUS Health is focused on developing drugs for rare diseases, starting with conditions that affect the kidneys.
The lead program KIACTA™, a novel drug candidate currently in a Phase III Confirmatory Study for the treatment of AA amyloidosis, a rare disease resulting in renal dysfunction that often leads to dialysis and death. KIACTA™ is partnered with global private equity firm Auven Therapeutics. The Phase III Confirmatory Study completed its enrollment in January 2015 and is expected to conclude in 2016.
KIACTA™ is also being developed as a treatment in a second indication called sarcoidosis, a rare inflammatory condition that affects the lungs. A Phase II trial is expected to begin in the second half of 2015.
In addition, BELLUS Health is developing Shigamab™, an antibody treatment for Hemolytic Uremic Syndrome caused by Shiga toxin-producing E. coli ("sHUS"). sHUS often leads to dialysis, chronic kidney disease and in some cases death, particularly in children. Shigamab™ pre-clinical studies for treatment of sHUS are currently underway.
BELLUS Health’s pipeline also includes a research-stage project for the treatment of AL amyloidosis, a rare disease in which amyloid protein builds up and causes dysfunction in various parts of the body.
BELLUS Health is based in Laval, Quebec and its shares trade under the ticker BLU on the Toronto Stock Exchange.
- See more at: http://www.bellushealth.com/English/about-bellus/...ash.Ky3FxYUt.dpuf http://www.bellushealth.com/English/about-bellus/...file/default.aspx
The lead program KIACTA™, a novel drug candidate currently in a Phase III Confirmatory Study for the treatment of AA amyloidosis, a rare disease resulting in renal dysfunction that often leads to dialysis and death. KIACTA™ is partnered with global private equity firm Auven Therapeutics. The Phase III Confirmatory Study completed its enrollment in January 2015 and is expected to conclude in 2016.
KIACTA™ is also being developed as a treatment in a second indication called sarcoidosis, a rare inflammatory condition that affects the lungs. A Phase II trial is expected to begin in the second half of 2015.
In addition, BELLUS Health is developing Shigamab™, an antibody treatment for Hemolytic Uremic Syndrome caused by Shiga toxin-producing E. coli ("sHUS"). sHUS often leads to dialysis, chronic kidney disease and in some cases death, particularly in children. Shigamab™ pre-clinical studies for treatment of sHUS are currently underway.
BELLUS Health’s pipeline also includes a research-stage project for the treatment of AL amyloidosis, a rare disease in which amyloid protein builds up and causes dysfunction in various parts of the body.
BELLUS Health is based in Laval, Quebec and its shares trade under the ticker BLU on the Toronto Stock Exchange.
- See more at: http://www.bellushealth.com/English/about-bellus/...ash.Ky3FxYUt.dpuf http://www.bellushealth.com/English/about-bellus/...file/default.aspx
03.11.16 19:59
#23
buran
1000 GEBONGT 1000
Amibuch http://www.ariva.de/bellus_health-aktie/times_and_sales?boerse_id=83 GrB
23.04.17 00:18
#24
buran
IIROC can make a decision to impose a temporary
suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly market. IIROC is the national self-regulatory organization which oversees all investment dealers and trading activity on debt and equity marketplaces in Canada. http://www.ariva.de/news/iiroc-trade-resumption-blu-6054887